The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease

Expert Opinion on Biological Therapy

Volumn 9, Issue 5, 2009, Pages 631-639

  Morel, Chantal F ^a,b   Clarke, Joe T R ^c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Agalsidase alfa; Enzyme replacement therapy; Fabry disease; Globotriaosylceramide; Pharmacodynamics

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; PLACEBO;

AUDITORY RESPONSE; CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ENZYME REPLACEMENT; FABRY DISEASE; GASTROINTESTINAL SYMPTOM; HEART FUNCTION; HUMAN; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PAIN; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VESTIBULAR FUNCTION;

ALPHA-GALACTOSIDASE; ANIMALS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; GENE THERAPY; HUMANS; ISOENZYMES;

EID: 67649122197     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590902902296     Document Type: Review

References (87)

1. Brady RO, Murray GJ, Moore DF, Schiffmann R. Enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2001;24(Suppl 2):18-24 (Pubitemid 33061628)
2. Brady RO, Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 2000;284:2771-2775
3. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004;34:236-242 (Pubitemid 38406640)
4. Desnick RJ, Ioannou YA, Eng CM. Eighth edition. Alfa-galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet al, Sly WS, Valle D, editors, The metabolic & molecular basis of inherited disease. New York: McGraw-Hill, 2001. p. 3733-3774
5. Ramaswami U, Whybra C, Parini R, et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006;95:86-92 (Pubitemid 43041735)
6. Hegemann S, Hajioff D, Conti G, et al. Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:654-662 (Pubitemid 44213833)
7. Hajioff D, Hegemann S, Conti G, et al. Agalsidase alpha and hearing in Fabry disease: data from the Fabry Outcome Survey. Eur J Clin Invest 2006;36:663-667 (Pubitemid 44213834)
8. Palla A, Hegemann S, Widmer U, Straumann D. Vestibular and auditory deficits in Fabry disease and their response to enzyme replacement therapy. J Neurol 2007;254:1433-1442 (Pubitemid 350112336)
9. Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart 2008;94:153-158 (Pubitemid 351211719)
10. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007;28:1228-1235 (Pubitemid 47343855)
11. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005;96:842-846 (Pubitemid 41319722)
12. Kampmann C, Wiethoff CM, Perrot A, et al. The heart in Anderson Fabry disease. Z Kardiol 2002;91:786-795 (Pubitemid 36015555)
13. Schwarting A, Dehout F, Feriozzi S, et al. Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 2006;66:77-84 (Pubitemid 44219432)
14. Dehout F, Schwarting A, Beck M, et al. Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr Suppl 2003;92:14-15 (Pubitemid 38134743)
15. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760 (Pubitemid 33032930)
16. Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States. Kidney Int 2002;61:249-255 (Pubitemid 34075152)
17. Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry renal disease: influence of α-galactosidase a activity and genetic mutations on clinical course. Medicine 2002;81:122-138 (Pubitemid 34218568)
18. Warnock DG, West ML. Diagnosis and management of kidney involvement in Fabry disease. Adv Chronic Kidney Dis 2006;13:138-147
19. Sodi A, Ioannidis AS, Mehta A, et al. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol 2007;91:210-214 (Pubitemid 46202871)
20. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775 (Pubitemid 33032933)
21. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-327 (Pubitemid 34596854)
22. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-1411 (Pubitemid 34263268)
23. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int 2003;64:801-807
24. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775 (Pubitemid 33032933)
25. Deegan PB, Baehner AF, Barba Romero MA, et al. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 2006;43:347-352
26. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008;93:112-128
27. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254 (Pubitemid 29058114)
28. Spada M, Pagliardini S, Yasuda M, et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006;79:31-40 (Pubitemid 43927374)
29. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006;8:539-548 (Pubitemid 44402030)
30. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med 2007;9:504-509 (Pubitemid 47282038)
31. Schiffmann R, Kopp JB, Austin HA III, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-2749 (Pubitemid 32525371)
32. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16 (Pubitemid 32634266)
33. Lee K, Jin X, Zhang K, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003;13:305-313 (Pubitemid 36592316)
34. Hopkin RJ, Bissler J, Grabowski GA. Comparative evaluation of α-galactosidase a infusions for treatment of Fabry disease. Genet Med 2003;5:144-153 (Pubitemid 36998676)
35. Wanner C. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies. Int J Clin Pract 2007;61:1234-1235 (Pubitemid 46934623)
36. Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE 2007;2:e598. Published online 11 July 2007, doi:10.1371/journal. pone.0000598 (Pubitemid 351279855)
37. Sakuraba H, Murata-Ohsawa M, Kawashima I, et al. Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice. J Hum Genet 2006;51:180-188
38. Lidove O, Joly D, Barbey F, et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract 2007;61:293-302 (Pubitemid 46271293)
39. Vedder AC, Breunig F, Donker-Koopman WE, et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008;94:319-325
40. Schiffmann R, Murray GJ, Treco D, et al. Infusion of α- galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 2000;97:365-370 (Pubitemid 30055837)
41. Beck M. Agalsidase alfa - a preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 2002;11:851-858 (Pubitemid 34618817)
42. Ries M, Clarke JT, Whybra C, et al. Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents. J Clin Pharmacol 2007;47:1222-1230 (Pubitemid 47459666)
43. Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2004;75:65-74
44. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002;62:1933-1946 (Pubitemid 35366149)
45. Thurberg BL, Randolph BH, Granter SR, et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004;122:900-908 (Pubitemid 38580992)
46. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine 2005;84:261-268 (Pubitemid 41368479)
47. Vedder AC, Linthorst GE, van Breemen MJ, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2007;30:68-78 (Pubitemid 46140228)
48. Murray GJ, Anver MR, Kennedy MA, et al. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab 2007;90:307-312 (Pubitemid 46241908)
49. Schiffmann R, Ries M, Timmons M, et al. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 2006;21:345-354 (Pubitemid 43159987)
50. Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol 2007;18:1576-1583 (Pubitemid 46717525)
51. Pastores GM, Boyd E, Crandall K, et al. Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 2007;22:1920-1925 (Pubitemid 47244761)
52. Mignani R, Feriozzi S, Pisani A, et al. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy. Nephrol Dial Transplant 2008;23(5):1628-1635 (Pubitemid 351767734)
53. Mignani R, Cagnoli L. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications. J Nephrol 2004;17:354-363 (Pubitemid 39106899)
54. Baehner F, Kampmann C, Whybra C, et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a Phase IIIB study. J Inherit Metab Dis 2003;26:617-627 (Pubitemid 38008966)
55. Dehout F, Roland D, Treille de GS, et al. Relief of gastrointestinal symptoms under enzyme replacement therapy [corrected] in patients with Fabry disease. J Inherit Metab Dis 2004;27:499-505 (Pubitemid 39140141)
56. Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004;34:838-844 (Pubitemid 39657931)
57. Ries M, Clarke JT, Whybra C, et al. Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 2006;118:924-932 (Pubitemid 46091613)
58. Hajioff D, Goodwin S, Quiney R, et al. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003;92:28-30 (Pubitemid 38134746)
59. Hajioff D, Enever Y, Quiney R, et al. Hearing loss in Fabry disease: the effect of agalsidase alfa replacement therapy. J Inherit Metab Dis 2003;26:787-794 (Pubitemid 38139379)
60. Hoffmann B, Schwarz M, Mehta A, Keshav S. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol 2007;5:1447-1453 (Pubitemid 350181595)
61. Jardim L, Vedolin L, Schwartz IV, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis 2004;27:229-240 (Pubitemid 38756339)
62. Jardim LB, Aesse F, Vedolin LM, et al. White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up. Arq Neuropsiquiatr 2006;64:711-717 (Pubitemid 44610624)
63. Jardim LB, Gomes I, Netto CB, et al. Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease. J Inherit Metab Dis 2006;29:653-659 (Pubitemid 44390428)
64. Ramaswami U, Wendt S, Pintos-Morell G, et al. Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 2007;96:122-127 (Pubitemid 46307392)
65. Schiffmann R, Hauer P, Freeman B, et al. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease. Muscle Nerve 2006;34:53-56
66. Kleinert J, Dehout F, Schwarting A, et al. Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int 2005;67:1955-1960 (Pubitemid 40577731)
67. Orteu CH, Jansen T, Lidove O, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol 2007;157:331-337 (Pubitemid 47083851)
68. Hoffmann B, Keshav S. Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr Suppl 2007;96:84-86 (Pubitemid 46481125)
69. Hoffmann B, Beck M, Sunder-Plassmann G, et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy - a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007;23:535-542 (Pubitemid 46956192)
70. Hoffmann B, Garcia de LA, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 2005;42:247-252 (Pubitemid 40380306)
71. Whybra C, Kampmann C, Krummenauer F, et al. The mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004;65:299-307 (Pubitemid 38443553)
72. Gold KF, Pastores GM, Botteman MF, et al. Quality of life of patients with Fabry disease. Qual Life Res 2002;11:317-327 (Pubitemid 34596854)
73. Beck M, Sunder-Plassman G, Mehta A, et al. Positive results from 3 years of enzyme replacement therapy with agalsidase-alfa in Fabry disease: data from FOS - the Fabry Outcome Study [abstract]. J Inherit Metab Dis 2005;28:164
74. West M, Nicholls K, Mehta A, et al. Clinical trial summary of agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009 In Press
75. Feriozzi S, Schwarting A, Sunder-Plassmann G, et al. Agalsidase alfa slows the decline in renal function in patients with Fabry disease. Am J Nephrol 2008;29:353-361
76. Basic-Jukic N, Coric M, Kes P, et al. Anderson-Fabry disease in kidneys from deceased donor. Am J Transplant 2007;7:2829-2833 (Pubitemid 350045777)
77. Basic-Jukic N, Kes P, Mokos I, Coric M. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease? Med Hypotheses 2009;72:476-477
78. Mougenot P, Lidove O, Caillaud C, et al. Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women: in reference to pharmacovigilance. Eur J Clin Pharmacol 2008;64:635-639
79. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with α galactosidase a. Heart 2006;92:357-360 (Pubitemid 43295106)
80. Moore DF, Altarescu G, Herscovitch P, Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol 2002;2:4 (Pubitemid 38729086)
81. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002;33:525-531 (Pubitemid 34123400)
82. Schiffmann R, Floeter MK, Dambrosia JM, et al. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve 2003;28:703-710 (Pubitemid 37484832)
83. Ries M, Gupta S, Moore DF, et al. Pediatric Fabry disease. Pediatrics 2005;115:e344-55 (Pubitemid 43373019)
84. Wendt S, Whybra C, Kampmann C, et al. Successful pregnancy outcome in a patient with Fabry disease receiving enzyme replacement therapy with agalsidase alfa. J Inherit Metab Dis 2005;28:787-788 (Pubitemid 41349266)
85. Linthorst GE, Hollak CE, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 2004;66:1589-1595 (Pubitemid 39298394)
86. Mehta A, Beck M, Kampmann C, et al. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab 2008;95:114-115
87. Benichou B, Goyal S, Sung C, et al. A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Mol Genet Metab 2009;96:4-12